1 citations
,
March 2004 in “Journal of the American Academy of Dermatology” ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
21 citations
,
September 2013 in “Current medicinal chemistry” HAC and BAC improve skin targeting and reduce diffusion without causing irritation.
May 2024 in “Indian Journal of Pharmacology” Tofacitinib effectively regrew scalp hair in an 11-year-old girl with alopecia areata.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
42 citations
,
January 1998 in “BioDrugs” Azathioprine's effectiveness and safety require careful monitoring and more research, especially regarding its use with corticosteroids and the role of TPMT status in patients.
September 2023 in “Journal of Cosmetic Dermatology” Topical cetirizine may help increase hair length in male pattern baldness and could be an alternative to minoxidil with fewer side effects.
1 citations
,
February 2025 in “Pediatric Dermatology” Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.
13 citations
,
August 2007 in “Bioorganic & medicinal chemistry letters” A new compound effectively inhibits human 5α-reductase 1.
October 2010 in “Epilepsy Currents” Ketogenic diet, neurosteroids, and HMGB1-TLR4 signaling pathway are potential targets for new epilepsy treatments.
13 citations
,
September 2014 in “BMC Complementary and Alternative Medicine” Tanshinone IIA helps protect skin tissue from low oxygen damage by boosting certain cell markers.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
20 citations
,
January 2000 in “Dermatologic Clinics” New psoriasis treatments are effective but come with side effects and risks.
January 2018 in “Journal of the American Academy of Dermatology” More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.
26 citations
,
December 1981 in “British journal of dermatology/British journal of dermatology, Supplement” Cyproterone acetate reduced hair growth in most hirsute females and made hair softer, thinner, and lighter.
39 citations
,
March 1976 in “British Journal of Dermatology” Intralesional steroid therapy is useful for treating various skin conditions.
April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
5 citations
,
June 2019 in “British Journal of Dermatology” Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
Cyproterone acetate is an effective treatment for women with acne, hair loss, and excessive hair growth.
5 citations
,
September 2020 in “Proceedings - Baylor University. Medical Center” Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
2 citations
,
January 2014 in “Advanced Biomedical Research” Oral isotretinoin and cyproterone compound are equally effective for treating acne in women with cutaneous hyperandrogenism.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
58 citations
,
July 1974 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Cyproterone acetate combined with ethinyl estradiol significantly reduced hirsutism in women.
1 citations
,
January 1980 in “Acta Dermato Venereologica” Oral tetracycline reduces fat breakdown in hair lipids.
Apraglutide and N-acetylcysteine (NAC) show promise in reducing cytarabine's harmful effects on organs.
5 citations
,
August 2018 in “PubMed” An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.
April 2025 in “Frontiers in Pharmacology” Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.
1 citations
,
January 2024 in “Pharmaceuticals” A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
May 2019 in “Journal of clinical oncology” Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.
May 2024 in “Reactions weekly”